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Abstract:  
Objective:  
Systematic lupus erythematosus (SLE) is characterized with various complications which can cause 
serious organ damage in the human body. Despite the significant improvements in disease 
management of the SLE patients, the non-invasive diagnosis is entire missing. In this study, we used 
urinary peptidomic biomarkers for early diagnosis of disease onset to improve patient risk 
stratification vital for effective drug treatment.  
Methods: Urine samples from patients with SLE, lupus nephritis (LN) and healthy controls (HC) were 
analyzed using capillary electrophoresis coupled to mass spectrometry (CE-MS) for state-of-art 
biomarker discovery. Results: A biomarker panel made up of 65 urinary peptides was developed that 
accurately discriminate SLE without renal involvement from HC patients. The performance of the 
SLE-specific panel was validated in a multicentric independent cohort consisting of patients without 
SLE but with different renal disease and LN. This resulted in area under the ROC curve (AUC) of 0.80 
(p<0.0001, 95%-CI 0.65-0.90) corresponding to a sensitivity and a specificity of 83% and 73%, 
respectively. Based on the end terminal amino acid sequences of the biomarker peptides, an in silico 
methodology was used to identify the proteases that were up or down regulated. This identified 
matrix metalloproteinases (MMPs) as being mainly responsible for the peptides fragmentation.  
Conclusion:  
A laboratory-based urine test was successfully established for early diagnosis of SLE patients. Our 
approach determined the activity of several proteases and provided novel molecular information 
that could potentially influence treatment efficacy  
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 Abstract  
 
Objective: Systematic lupus erythematosus (SLE) is characterized with various complications  
which can cause serious organ damage in the human body. Despite the significant  
improvements in disease management of the SLE patients, the non-invasive diagnosis is entire  
missing. In this study, we used urinary peptidomic biomarkers for early diagnosis of disease  
onset to improve patient risk stratification vital for effective drug treatment.  
 
Methods: Urine samples from patients with SLE, lupus nephritis (LN) and healthy controls (HC)  
were analyzed using capillary electrophoresis coupled to mass spectrometry (CE-MS) for state- 
of-art biomarker discovery.  
 
Results: A biomarker panel made up of 65 urinary peptides was developed that accurately  
discriminate SLE without renal involvement from HC patients. The performance of the SLE- 
specific panel was validated in a multicentric independent cohort consisting of patients without  
SLE but with different renal disease and LN. This resulted in area under the ROC curve (AUC) of  
 
0.80 (p<0.0001, 95%-CI 0.65-0.90) corresponding to a sensitivity and a specificity of 83% and  
73%, respectively. Based on the end terminal amino acid sequences of the biomarker peptides,  
an in silico methodology was used to identify the proteases that were up or down regulated.  
This identified matrix metalloproteinases (MMPs) as being mainly responsible for the peptides  
fragmentation.  
Conclusion: A laboratory-based urine test was successfully established for early diagnosis of  
SLE patients. Our approach determined the activity of several proteases and provided novel  
molecular information that could potentially influence treatment efficacy.  
Keywords: SLE, urine peptide biomarkers, protease prediction.  
Introduction  
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by  
numerous clinical pathologies with an overall incidence up to 1000 cases per 100,000  
individuals in the general population [1]. Inflammation often involves a broad range of vital  
organs and causes serious complications with increased mortality and morbidity [2]. The most  
common organ manifestation is lupus nephritis (LN), affecting approximately 40% of SLE  
patients [3-5]. Despite advances in the latest therapies, significant and variable organ  
involvement from patient-to-patient is evident [6]. These facts indicate a need for improvement  
of the management of patients diagnosed with SLE, possibly guided by appropriate biomarkers.  
Pathogenesis of SLE is associated with multiple complex processes affecting not only the skin,  
but also musculoskeletal system, kidneys and central nervous system (CNS) [6]. Autoantibody  
accumulation, increase of abundance of proteins from the complement system and activation  
of macrophages are some of the disrupted molecular responses that lead to inflammation and  
aggressive disease progression which is often unresponsive to therapies [7]. These effects  
together with an increase of cell proliferation, production of numerous extracellular proteins,  
pro-inflammatory cytokines and chemokines, cause destructive changes in the functional  
mechanisms indicative of the renal tubular damage, vascular injury, tubulointerstitial  
inflammation, and fibrosis [8, 9]. Although the knowledge about these factors resulted in better  
medical care of SLE patients during the last decades, the prognosis of disease outcome is still  
not optimal [10]. Factors impacting the moderate clinical efficiency of intervention may also be  
the higher toxicity of the current medications utilized in intervention [11]. In spite of the efforts  
for improved strategies and specific molecular drug targeting for immunopathogenic pathways,  
the data on targeted therapies for SLE onset activity are generally disappointing [12, 13]. In  
order to prevent later stage SLE-related complications and comorbidities, identification of novel  
and more reliable panel of surrogate biomarkers reflecting complex underlying processes could  
be beneficial for patients in guiding treatment or accessing interventional responses, also  
avoiding possibly unnecessary high-dose drug treatment during long-term disease course.  
Currently, the most common biomarkers for monitoring disease activity and its progression  
appear of moderate advantage. Standard biomarkers such as anti-double stranded (ds) DNA  
antibodies and complement levels show association with outcome/ prognosis of SLE-associated  
comorbidities and value in clinical practice. However, a number of studies have demonstrated  
lower specificity of these laboratory tests i.e. serum anti-dsDNA antibodies and suggested  
moderate value in treatment decision making [14, 15]. In a similar manner, complement 3 (C3)  
and 4 (C4) measurements provided weak performance for diagnosis of SLE [16, 17]. Therefore,  
additional non-invasive methods appear urgently required to provide important information  
about pathogenesis of SLE and improve the management of these patients particularly when  
the disease is at an early stage.  
Urine, specifically urinary peptides for biomarker development, have multiple advantages over  
current available options, as outlined in detail in several recent publications [18-21]. Among  
these are the opportunity for multiple and non-invasive sampling, the high stability of the  
urinary peptide biomarkers. When dealing with a disease that, as described above, has multiple  
complex processes, a biomarker containing multiple components can better reflect these wide- 
ranging changes. In addition to these specific advantages, there is currently moving towards  
true “liquid biopsy” as recently introduced based on available > 20000 subject datasets that can  
enable efficient in silico assessment of renal involvement in various diseases including SLE [22].  
These advantages also render urinary biomarkers as a promising way for monitoring of disease  
activity, and drug response.  
In the past, we have demonstrated the association of urinary peptides with inflammatory  
diseases like rheumatoid arthritis [23] and also graft-versus-host-disease [24]. A similar study  
has recently identified biomarkers specific for LN that enabled differentiating of LN from other  
chronic kidney diseases [25]. Based on these data, we generated the hypothesis that urinary  
peptides could reflect SLE, and may have value in diagnosis of SLE. To test this hypothesis, we  
used capillary electrophoresis coupled to mass spectrometry (CE-MS) to evaluate the urinary  
proteomic profiles of samples collected from patients with SLE and healthy controls (HC), aiming at  
identifying peptides associated with SLE. Such peptides could subsequently be used as  
biomarkers to assess the success of intervention, possibly even guiding intervention towards  
personalized therapy.  
Materials and methods  
2.1 Sample characteristics  
In total 173 urine samples were used in this study. Samples collected from SLE patients with no  
renal involvement (n=34) and matched (for age, gender, and eGFR ) HC (n=58) were used for  
the identification of potential biomarkers and development of a classifier of SLE. In addition,  
samples from 36 subjects with SLE and impaired renal function (LN) were employed to verify  
the potential biomarkers advanced for SLE. The participants were selected from longitudinal  
and prospective Study of biological Pathways, disease Activity and Response markers in  
patients with systematic lupus Erythematosus (SPARE), approved by the Johns Hopkins  
University School of Medicine Review Board and funded by R01AR043727 and R01AR069572,  
from NCT01731054, a prospective non-interventional study evaluating MRI imaging in patients  
with LN and from Bioreclamation (Baltimore MD).  
 
For subsequent validation, samples from LN patients (n=23) and matched (for age, gender, and  
eGFR) non-SLE patients with different renal diseases (n=22) were employed. This sub-group of  
participants was selected from Mosaiques Human Urine Database [26]. The study was  
conducted according the guidelines of Declaration of Helsinki and consent from all participants  
was obtained.  
 
2.2 Sample preparation  
Immediately before preparation, the samples were thawed, 0.7 mL aliquots were removed and  
diluted with 0.7 mL 2 M urea, 10 mM NH4OH containing 0.02% SDS. Removal of the high  
molecular weight polypeptides were performed by filtering using Centrisart ultracentrifugation  
filter devices (20 kDa molecular weight cut-off; Sartorius, Goettingen, Germany) at 3,000 × g  
until 1.1 mL of filtrate was obtained. Subsequently, filtrates were desalted using PD-10 column  
(GE Healthcare, Sweden) equilibrated in 0.01% NH4OH in HPLC-grade water. Finally, samples  
were lyophilized and stored at 4°C.  
 
2.3 CE-MS analysis  
Shortly before the CE-MS analysis, lyophilisates were resuspended in HPLC-grade water to a  
final protein concentration of 0.8 µg/µL, based on the BCA assay (Interchim, Montlucon,  
France). CE-MS analysis was performed as described [27] using a P/ACE MDQ capillary  
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line coupled to a MicroTOF MS  
(Bruker). The electrospray ionization (ESI) source (Agilent Technologies, Palo Alto, CA, USA) was  
grounded, and the ion spray interface potential was set –4.5 kV. CE-MS data acquisition ere  
automatically controlled by the CE via contact-close-relays. Spectra were accumulated every  
3 s, over a range of mass to charge ratio (m/z) 350 to 3000 [28-30].  
 
2.4 Data processing and cluster analysis  
CE-MS data was processed sing MosaiquesVisu software [31]. Migration time and ion signal  
intensity (amplitude) were normalized using “internal polypeptide standards”, as described  
[32]. The resulting peak list characterizes each peptide by its molecular mass [Da], normalized  
migration time [min] and signal intensity. All detected polypeptides were deposited, matched,  
and annotated in a Microsoft SQL database. Cluster analysis was used to align peptides by mass  
across samples. During initial clustering, peptides across different samples were considered  
identical, if mass deviation was <50 ppm for small or 75 ppm for larger peptides. Due to analyte  
diffusion effects, CE peak widths increase with CE migration time. In the data clustering process,  
this effect was considered by linearly increasing cluster widths over the entire  
electropherogram (19 min to 45 min) from 2-5%.  
 
2.5. Sequencing  
Determination of the primary structure of the urinary peptides was performed using LC-MS/MS  
and CE-MS/MS, as described in detail previously [33]. In short, samples if separated by LC, were  
first loaded onto a Dionex C18 nano trap column (100 µm x 2 cm 5 µm) at a flowrate of 5 µl/min  
and subsequently washed off into an Acclaim PepMap C18 nano column (75 µm x 15 cm, 2 µm  
100 Å) at a flowrate of 0.3 µm/min using a Ultimate 3000 RSLC autosampler and pump system  
(Dionex, Camberley UK). The samples were eluted with a gradient of solvent A:97.9% water,  
0.1% formic acid, 2% acetonitrile verses solvent B: 80% acetonitrile, 19.9% water, 0.1% formic  
acid starting at 1% B for 5 min rising to 20% B after 90 min and finally to 40%B after 120 min.  
Once loaded onto the trap column the samples were then washed off into analytical column.  
The trap and nano flow column were maintained at 35 oC in a column oven in the Ultimate  
3000 RSLC [34]. Alternatively, samples were injected and separated using a P/ACE MDQ  
capillary electrophoresis system (Beckman Coulter, Fullerton, USA) as described above for CEMS  
[27].  
 
The eluent from the CE was directed to a hybrid mass spectrometer LTQ Orbitrap Velos  
(Thermo Finnigan, Bremen, Germany) via Agilent ESI sprayer as described above. The eluent  
from LC was directed to LTQ Orbitrap Velos via a Proxeon nano ESI source (Thermo Fisher  
Hemel UK) operating in positive ion mode. The ionization voltage was 2.5 kV and the capillary  
temperature was 200 ºC. The mass spectrometer was operated in MS/MS mode scanning from  
380 to 2000 amu. The fragmentation was performed with higher-energy collision dissociation  
(HCD) method at 35% collision energy. The ions were selected for MS2 using a data dependant  
method with a repeat count of 1 and repeat and exclusion time of 15 s. Precursor ions with a  
charge state of 1 were rejected. The resolutions were set at 60,000 (MS1) and 7,500 (MS/MS).  
 
CE and LC Data files from experiments performed on the HCD-enabled LTQ Orbitrap Velos were  
searched against the UniProt human database (released 01/07/2016) using Thermo Proteome  
Discoverer version 1.2, without any proteolytic enzyme specified. No fixed modification was  
selected, oxidation of methionine and hydroxylation of proline were set as variable  
modifications. Mass error window of 10 ppm and 0.05 Da were allowed for MS and MS/MS,  
respectively [34].  
 
For further validation of obtained peptide identifications, CE-MS/MS analysis was performed on  
selected peaks, and the strict correlation between peptide charge at the working pH of 2 and  
CE-migration time was utilized to minimize false-positive identification rates [35]. Additionally,  
estimated CE-migration time of the sequence candidate based on its peptide sequence (number  
of basic amino acids) was compared to the experimental migration time. CE-migration time  
deviations below ±2 min corresponding to the CE-MS measurement were accepted.  
2.6 Statistical analysis  
Statistical analysis for selecting SLE specific peptides was performed using R-based  
programming language. Unadjusted p-values of the CE intensities spectra were calculated  
applying natural logarithm for transformation and Gaussian approximation to test distribution.  
Their p-values were calculated using Wicoxcon Rank Sum test followed by multiple testing using  
the method described by Benjamini and Hochberg [36]. Generation of the SLE-specific classifier  
was done using support vector machine (SVM)-based Mosa Cluster software [37]. Classification  
scores provided by this software were expressed as numerical values quantifying the Euclidean  
distance of the data point to the maximal margin of the separation hyperplane among cases  
and controls in multidimensional space, defined by the classification score generated in the  
training cohort. All further statistical calculations were performed using MedCalc (version  
12.7.5.0, MedCalc Software, Mariaakerke, Belgium; www.medcalc.be).  
 
2.7 In silico protease prediction  
Prediction of the potential proteases responsible for the generation of naturally occurring  
peptides associated with SLE was performed using Proteasix bioinformatics software [38].  
Briefly, N and C terminal cleavage sites of the SLE specific peptidesere used to calculate in silico  
the probability of certain protease involved in proteolytic processing and breakdown of their  
paternal proteins. The proteases which were previously observed by Proteasix were considered  
as a high confidence. If not then the specificity of the prediction was evaluated against a  
probability threshold generated by randomly mapping more than 6000 octapeptides sequences  
using MEPROS database list which contain the information about the frequency of each amino  
acid at every position in the experimentally confirmed cleavage site of a given protease. Based  
on mean intensities of the detected peptide markers, activity of the proteases was calculated  
for each patient and compared between patients groups. Proteases with = 2 cleavage site  
association and predicted as a high confidence were further investigated [39]. Mann-Whitney  
test with adjusted p-values <0.05 was applied to identify the proteases with a significant  
proteolytic activity responsible for the observed protein/peptide fragmentation.  
 
3. Results  
3.1 CE-MS analysis of the urine polypeptides  
All urine samples were analyzed as described [27, 40]. The mass and retention time of all  
peptide markers detected were calibrated and harmonized with the human urinary proteome  
database [26, 27, 40] to allow consistent data evaluation and comparison with previous results.  
Schematic representation of the study design is given in Figure 1. All recorded intensities  
represented in a form of peaks with their appropriate mass and retention time of each patients  
group (HC and SLE) are shown in Figure 2.  
 
3.2 Biomarker identification  
In order to detect the SLE-specific peptides, the peptide marker intensities obtained from 34  
samples of patients with SLE were compared to the intensities of 58 HC (Figure 1). Demographic  
characteristics of the patient groups are shown in Table 1. Only peptides with the frequency of  
occurrence >50% in at least one of the groups were investigated. This resulted in the  
identification of just 95 peptides that showed significantly different intensities between the  
compared patient groups (adj. p<0.05). Due to insufficiency of sample collection and lack of  
clinical data from the same group of patients used for identification of the potential  
biomarkers, we investigated the intensities of the 95 potential biomarkers in an additional 36  
samples from SLE patients with renal involvement (LN). By doing so, and performing additional  
statistical analysis, we found out that 65 of the biomarker candidates were SLE specific and  
remaining 30 showed weak correlation in regard to the disease and therefore were discarded.  
The verified 65 biomarker candidates were retained as likely SLE-specific.  
 
3.3 Peptide sequence information and generation of the SLE diagnostic panel  
Tandem mass spectrometry as methodology is used for breaking down precursor ions into  
smaller fragments in order to reveal chemical structures. This approach enabled sequence  
information for 47 out of the 65 biomarkers candidates listed in Table 2. In total, 37 of the 47  
sequenced peptides originated from different collagen proteins. Almost all (only one exception)  
were decreased in patients with SLE. In addition, 5 uromodulin fragments were defined and  
they were increased in SLE patients compared to HC. Two different fragments of fibrinogen  
alpha were also defined, while one fragment was increased the other one was decreased in SLE  
patients. The distribution of all 65 biomarker candidates in HC and SLE patients is shown in  
Figure 3.  
 
Generation of the SLE -diagnostic panel with 65 peptide markers was carried out by using  
machine learning algorithms (SVM modelling) commonly employed for classification analysis.  
This is especially important for categorization of patients into those with or without presence of  
disease. Therefore, the peptide marker panel developed herein was applied to the discovery  
cohort (n=92) and achieved an area under the receiver operating characteristics curve (AUC) of  
 
0.99 in discrimination of SLE from HC. To assess the value and validity of this panel, its  
performance was assessed in the independent multicentric validation cohort (n=45) including  
LN and non-SLE patients. Baseline characteristics of the validation set are shown in table 3. This  
analysis resulted with an AUC of 0.80 (p<0.0001, 95%-CI 0.65-0.90) corresponding to a  
sensitivity and a specificity of 83% and 73%, respectively (Figure 4). These findings, clearly  
demonstrated that the urinary peptides are associated with SLE, and support the validity of the  
approach throughout the classifier development.  
3.4 In silico protease identification  
To obtain additional information on molecular pathways underlying SLE pathophysiology, we  
next tried to identify in silico the proteases likely responsible for the generation of the 47 SLE- 
specific urinary peptide markers with sequences identified, and their relative activities in SLE  
and HC conditions. Mean intensities of these 47 biomarkers in both groups revealed 8  
proteases with increased cleavage activity in SLE relative to HC as shown in Table 4. Majority of  
the proteases were identified as matrix metalloproteinases (MMPs), with the most prominent  
activity of MMP 9. We also found increased activity of serine protease hepsin and decreased  
activity of kallikrein-2 in SLE as compared to HC.  
4. Discussion  
The course of SLE is manifested with variety and complex molecular features that make  
management of the disease challenging [41]. Although the most relevant and accurate clinical  
procedures in assessing SLE complications require regular physical examination and laboratory  
analysis, SLE is characterized as a serious and common disease with poor long-term prognosis.  
In this study, we set out to identify urinary biomarkers associated with SLE, that may be of  
value in disease management. We first developed a SLE-specific panel of 65 peptides that  
showed highly significant association with SLE in an independent and multicentric validation. Of  
the 65 peptides making up the SLE panel we identified the amino acid sequences of 47 of them.  
Based on these data, urinary peptides, specifically the panel presented here, has the potential  
to improve early diagnosis in clinical settings of SLE, and may provide further insights into the  
pathophysiological processes implicated in SLE.  
 
Current laboratory diagnostic tests based on the serological determination of anti-double  
stranded DNA antibodies as well as complement levels for identification of SLE appeared to be  
insufficient [14, 15, 17]. In particular, sensitivity and specificity measurements of these  
biomarkers among all SLE patients were ranging from 53-100% and 50-71% respectively,  
depending on different studies and tests used for monitoring of SLE disease activity. It is  
essential to note that overall performance of the current molecular signatures is highly variable  
and of moderate accuracy, demonstrated by the positive predictive value below 38% [14]. We  
therefore decided to perform a urinary proteome analysis of clinically well-defined SLE and LN  
patients collected from SPARE and NCT01731054. The panel developed herein yielded good  
accuracy when applied to an independent set of LN and non-SLE patients with various renal  
complications.  
 
Using tandem mass spectrometry (LTQ-Orbitrap Velos), 47 out of 65 (72%) of the potential  
urinary biomarkers for SLE could be identified. It is likely that the peptides that remained  
unidentified harbour post-translational modifications, which, via their impact on the molecular  
mass, interfere with sequence assignment in MS/MS analysis [34]. The majority of the small  
naturally occurring peptides that were identified originate from different forms of collagen. We  
found 23 fragments of collagen alpha (I) chain, 3 of collagen alpha (II) chain, 4 of collagen alpha  
 
(III) chain, 2 of collagen alpha (III) chain. This is not too surprising due to several reasons. First,  
collagen fragments are the most abundant peptides in urine [21]. Second, collagen, as an  
abundant protein in the extracellular matrix, is a major target of proteolysis in inflamed organs  
[42]. In addition, significant changes in specific fibrinogen alpha-derived peptides were  
observed, one down-regulated and one up-regulated in SLE compared to HC. Further, 5  
uromodulin fragments were found to be significantly upregulated in SLE.  
Although the most frequent proteins identified in our study were collagens, little is known  
about the mechanism and breakdown of these proteins. As urinary peptides are analyzed intact,  
that is they have not been subject to enzymatic treatment with trypsin, further information  
on the production of the amino acid sequences can be obtained by analysis of their end  
terminal amino acids. By matching the cleavage site of the identified peptides with proteases  
known to produce these end terminal sequences, we can identify increased and decreased  
protease activity . This was carried out using an open source software package Proteasix [38].  
We performed the in silico prediction of the protease activity and identified the enzymes potentially  
responsible for the peptide fragmentations. Our protease activity analysis predicted  
significant increased activity of 8 proteases in SLE patients. Among them were matrix 
metalloproteinase  
MMP -3,-8,-9,-12,-13 and 14 which were previously demonstrated to be involved in  
extra cellular matrix (ECM) proteolysis [43]. A recent study confirmed the prominent activity of  
MMP 9 in SLE patients compared to healthy controls which may play a role in the pathogenesis  
of the disease [44]. In contrast to our prediction, normal levels of MMP 3 have been reported in  
patients with SLE, while significantly increased levels were noted during treatment with 
corticosteroids  
[45]. MMP 8 and MMP 13 collagenases were reported to have an ability to cleave fibrillar  
collagen proteins [43]. However, the complexity of MMPs role and their localization has not  
been specified, although the majority of the identified proteases in this study were expressed in  
a variety of renal compartments. So far, there has been no evidence of their implication in SLE  
and this requires further investigations.  
The current work has several potential limitations. First of all, the study was performed in a  
relatively small sample size. In order to evaluate in-depth the performance of the classifier, 
proteomic  
analysis in larger patient groups is needed. Secondly, although in our study design we  
have used an external validation cohort, which consists of patients with renal involvement, an  
appropriate cohort of SLE patients without renal impairment and healthy controls is necessary  
to further assess the value of the biomarkers. Thirdly, relevant clinical data, i.e. complement C3  
and C4 measurements, are not available for all patients and are entirely missing for the healthy  
individuals. Such data would be required for comparative analysis with the urinary proteome  
measurements with the current clinical parameters, to properly assess a possible significant  
advantage or added benefit. However, the data available from this proof-of-concept study  
clearly demonstrate a highly significant association of specific urinary peptides with SLE and  
certainly warrant further (prospective) validation studies. Such studies can address the question  
of the specific value of urinary peptide biomarkers and classifiers in the context of SLE patient  
management.  
 
Collectively, our data demonstrated the utility of multi-marker panel approach in discrimination  
of SLE patients from healthy individuals and further support the high-priority need for such urinary  
biomarkers to be investigated for drug development and monitoring of treatment response  
and ultimately improving personalized medicine.  
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 Table 1. Demographic and clinical characteristics of the patients from discovery cohort  
 
  HV (58) SLE  (34) LN (36) 
P value 
LN vs nonrenal 
SLE 
LN vs HV 
nonrenal 
SLE vs 
HV 
Sex 
F/M: 55/3 
(94% F) 
F/M: 32/2 
(94% F) 
F/M: 34/2 (94% F)       
Age 37.74±11.46 40.68±10.24 41.44±11.61       
Race* 33C, 21B, O4 
23C, 9B, 1A, 
1O, 1U 
17C, 14B, 2A, 3O       
uPCR 0.04±0.02 0.04±0.05 2.88±2.29 < 0.000001 < 0.000001   
sCre 0.82±0.21 0.78±0.16 1.52±1.25 0.001418 0.010633   
eGFR 91.37±20.05 92.28±23.43 61.8±37 0.000182 0.001869   
SLEDAI Global Score** NA 2.97±3.05 7.61±3.99 0.000052     
rSLEDAI** NA 0 4.89±2.59 0.077739     
PGA** NA 1.84±0.35 2.08±0.41       
 
Table 2. List of sequenced peptide markers specific for SLE. 
Mass [Da] 
CE-
Time 
[Min] 
adjusted 
p-value 
(BH) 
mean 
Amplitude 
HC 
 
mean 
Amplitu
de SLE 
 
Fold 
chang
e 
SLE/H
C 
 
Sequence Protein name 
892.27 35.19 3.71E-03 484.49 1032.98 2.13 GDGDGDGDAD ATPase WRNIP1 
840.4 25.36 2.10E-02 45.29 11.27 0.25 DGKTGPpGP Collagen alpha-1(I) chain 
1050.48 26.93 3.21E-02 828.04 551.61 0.67 DGRpGPpGPpG Collagen alpha-1(I) chain 
1070.5 36.38 4.37E-02 198.98 54.17 0.27 
GPpGPpGpPGP
P 
Collagen alpha-1(I) chain 
1080.5 25.69 4.18E-03 142.23 50.91 0.36 DRGEpGPpGPA Collagen alpha-1(I) chain 
1137.51 26.5 2.01E-02 112.41 27.72 0.25 GDRGEpGPpGP Collagen alpha-1(I) chain 
A 
1154.51 25.72 4.64E-02 472.3 148.69 0.31 
PpGEAGKpGEQ
G 
Collagen alpha-1(I) chain 
1171.51 29.04 2.10E-02 67.77 31.24 0.46 
DGAKGDAGApG
ApG 
Collagen alpha-1(I) chain 
1286.54 29.33 3.43E-02 114.03 40.67 0.36 
DGQpGAKGEpG
DAG 
Collagen alpha-1(I) chain 
1444.67 20.06 1.13E-02 75.65 15.95 0.21 
SpGRDGSpGAK
GDRG 
Collagen alpha-1(I) chain 
1491.73 39.89 2.39E-02 839.27 453.22 0.54 
VGpPGPPGpPG
PPGPPS 
Collagen alpha-1(I) chain 
1997.91 25.16 3.00E-03 130.76 22.92 0.18 
NSGEPGApGSK
GDTGAKGEpGP 
Collagen alpha-1(I) chain 
2096.91 32.82 3.00E-03 271.66 47.32 0.17 
GApGNDGAKG
DAGApGApGSQ
GApG 
Collagen alpha-1(I) chain 
2128.98 26.92 2.72E-02 91.63 38.42 0.42 
DGKTGpPGPAG
QDGRpGPpGPp
G 
Collagen alpha-1(I) chain 
2308.01 27.33 1.86E-02 241.66 101.23 0.42 
ADGQpGAKGEp
GDAGAKGDAGP
pGpA 
Collagen alpha-1(I) chain 
2423.09 27.7 2.10E-02 467.7 281.13 0.60 
LDGAKGDAGPA
GpKGEpGSpGE
NGApG 
Collagen alpha-1(I) chain 
2639.29 21.44 2.01E-02 381.82 197.06 0.52 
KEGGKGPRGET
GPAGRpGEVGP
pGPpGP 
Collagen alpha-1(I) chain 
3264.57 25.7 4.61E-02 1020.58 646.7 0.63 
AAGEpGKAGER
GVpGPpGAVGP
AGKDGEAGAQG
PPGP 
Collagen alpha-1(I) chain 
3416.59 31.96 2.01E-02 811.86 150 0.18 
GPpGADGQPGA
KGEpGDAGAKG
DAGPPGpAGPA
GPPGpIG 
Collagen alpha-1(I) chain 
1341.57 29.94 2.25E-03 154.08 26.65 0.17 
GADGQPGAKGE
pGDA 
Collagen alpha-1(I) chain 
1359.61 23.18 4.78E-02 138.64 44.69 0.32 
GPpGPSGNAGP
pGpPG 
Collagen alpha-1(I) chain 
1526.69 23.89 3.43E-02 127.66 61.17 0.48 
DGQPGAKGEpG
DAGAKG 
Collagen alpha-1(I) chain 
1586.73 29.02 2.35E-02 108.81 46.98 0.43 
RGEQGpAGSpG
FqGLP 
Collagen alpha-1(I) chain 
1636.74 22.52 2.35E-02 9684.36 
15102.6
5 
1.56 
GSpGSpGPDGK
TGPpGPAG 
Collagen alpha-1(I) chain 
1874.83 30.89 2.10E-02 97.62 30.81 0.32 
GPSGpQGpGGp
PGPKGNSGEP 
Collagen alpha-1(I) chain 
1066.48 25.98 2.90E-02 256.07 33.71 0.13 GEDGRpGPpGP Collagen alpha-1(II) chain 
1848.8 30.73 2.35E-02 92.45 42.85 0.46 
QGLpGpPGPSG
DqGASGpAGP 
Collagen alpha-1(II) chain 
3266.48 29.96 2.76E-02 67.14 25.4 0.38 
PGLGGNFAAqm
AGGFDEKAGGA
QLGVMqGPMG
PM 
Collagen alpha-1(II) chain 
1623.73 24.09 1.52E-02 5591.69 7923.12 1.42 
DGApGKNGERG
GpGGpGP 
Collagen alpha-1(III) chain 
2062.93 26.46 2.81E-03 737.51 329.2 0.45 
DAGAPGApGGK
GDAGApGERGp
PG 
Collagen alpha-1(III) chain 
980.5 22.53 4.44E-03 56.91 19.24 0.34 PGKDGPRGPT Collagen alpha-1(III) chain 
1357.57 29.93 4.64E-02 165.66 62.09 0.37 
SpGSPGYQGpP
GEP 
Collagen alpha-1(III) chain 
1837.79 30.66 3.14E-02 144.09 46.52 0.32 
pGPpGTSGHpG
SPGSPGYQG 
Collagen alpha-1(III) chain 
1657.74 23.04 7.50E-03 155.84 17.14 0.11 
PGVpGpKGDpG
FQGmPG 
Collagen alpha-1(IV) chain 
2739.23 28.46 1.86E-02 112.75 43.82 0.39 
EqGpPGPTGPQ
GPIGQPGpSGA
DGEPGpR 
Collagen alpha-1(V) chain 
935.45 23.82 2.56E-03 159.86 43.3 0.27 GRpGPpGPpG 
Collagen alpha-1(XXVI) 
chain 
1576.75 19.51 4.16E-02 619.15 394.31 0.64 
EDGHpGKPGRp
GERG 
Collagen alpha-2(I) chain 
3801.79 33.48 2.40E-02 339.76 164.86 0.49 
DQGPVGRTGEV
GAVGPpGFAGE
KGpSGEAGTAG
PPGTpGPQG 
Collagen alpha-2(I) chain 
1669.69 21.45 1.50E-02 733.4 228.69 0.31 
DEAGSEADHEG
THSTK 
Fibrinogen alpha chain 
1825.79 20.13 1.13E-02 1472 2582.59 1.75 
DEAGSEADHEG
THSTKR 
Fibrinogen alpha chain 
1409.58 22.11 1.63E-02 10788.15 
15894.8
5 
1.47 
SGQEGAGDSPG
SQFS 
Forkhead box protein O1 
2187.96 39.54 4.35E-02 1185.26 1832.87 1.55 
HEGEPTTFQSW
PSSKDTSPA 
Mucin-12  
1911.05 25.23 1.51E-06 14925.34 
60713.1
9 
4.07 
SGSVIDQSRVLN
LGPITR 
Uromodulin 
2039.13 21.83 3.00E-03 289.26 955.5 3.30 
SGSVIDQSRVLN
LGPITRK 
Uromodulin 
1013.37 25.06 4.49E-02 2516.87 5375.8 2.14 IQDYDECE Uromodulin 
1467.81 24.78 2.38E-05 249.04 1252.24 5.03 DQSRVLNLGPIT Uromodulin 
R 
1580.9 24.89 6.40E-05 355.52 1688.38 4.75 
IDQSRVLNLGPIT
R 
Uromodulin 
 
Table 3. Baseline characteristics of the validation set 
 Variable 
Non- SLE 
with other 
CKD (22) 
LN (23) 
 
P-value 
Sex 
F/M: 14/8 
(51% F) 
F/M: 18/5 
(78% F) 
 
p=0.2898 
Age 42.28.±7.13 37.34±13.25 
 
p=0.1299 
eGFR 94.14±18.77 94.47±19.70 
 
p=0.9534 
 
Table 4. Shown are proteases involved in fragmentation of the 47 biomarkers with their 
number of N or C termini cleavage sites characteristic for each protease; estimated fold 
change difference based on peptide mean intensities in SLE vs HC patients groups and 
adjusted p-value calculated by Mann Whitney test.  
Proteases Number of cleavage 
sites 
Fold change (SLE/HC) p-value 
MMP 3 3 1.36 p=0.0159 
MMP 8 5 1.50 p=0.0057 
MMP 9 8 3.58 p<0.0001 
MMP 12 4 1.98 p=0.0001 
MMP 13 5 1.60 p=0.0006 
MMP 14 2 1.68 p=0.0011 
KLK 3 0.64 p=0.0510 
HPN 2 1.33 p=0.0043 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure Legends 
 
Figure 1: Schematic study design depicting all patients used for generation of the 65 
diagnostic biomarker panel without renal involvement and its validation in independent 
patient cohort. 
 
Figure 2: Group specific contour plots of SLE and HC cohort (upper panel). Each consisting of 
digitally compiled data sets of urine samples in a 3D depiction. Molecular mass of the 
analyzed polypeptides (kDa) in logarithmic scale is plotted against the CE migration time 
(min) with MS signal intensity in z-axis.  
 
Figure 3: Group specific contour plots of the defined and validated 65 specific peptides for 
SLE. Showed are compiled data sets of urine samples in a 3D depiction. Molecular mass of 
the analyzed polypeptides (kDa) in logarithmic scale is plotted against the CE migration time 
(min) with MS signal intensity in z-axis.  
Figure 4: Receiver operating characteristic (ROC) curves of the diagnostic peptide biomarker 
panel used to discriminate patients having SLE from those without in a) the development 
cohort consisting of 34 SLE and 58 HC patients after total cross-validation and in b) the 
validation cohort of 23 LN and 22 non-SLE patients with multiple renal diseases.   
 
